

“Seven Boxers” fighting stocks

- “Seven Boxers” stocks to outperform SET: OR, IVL, PTG, IVL, SCC, CPN, SFLEX, PJW, NER
- Distressed valuations on P/BV justified their limited downsides
- Visible earnings upsides on sound strategies, industry rebounds, and lower risks

Distressed valuation analysis revealed our “Seven Boxers” stocks

SET index continues its sideway down to stay below 1,200, closing at 1,189 on 6 Mar-25. As share prices of most SET 50 stocks have sharply plunged by over 50% from their recent peaks, we conducted an asset-based valuation check to see whether any stock could be good buying opportunities based on three criteria – discount to book value, visibility of net profit rebound, and low risk from external factors. Our findings are OR, PTG, IVL, SCC, CPN, SFLEX, PJW, and NER.

Deep discounts to book value using asset-based valuation

Amid the low earnings visibility, depressed industry margin outlook, and rising risks from politics and regulations, we think the asset-based (P/BV, NAV), rather than earnings-based (P/E, EV/EBITDA) valuation methodologies will be more appropriate to assess the downside risks of stocks whether they are deeply undervalued. Our analysis indicated that the stocks under our coverage that currently trade at deep discounts are 1) OR at 1.1 P/BV, its historical bottom (HB); 2) PTG at 1.3x P/BV (HB); 3) IVL at 0.8x P/BV; 4) SCC at 0.4x P/BV (HB), 5) CPN at 2.2x P/BV, near HB; 6) SFLEX at 2.2x P/BV (HB); 7) PJW at 0.9x P/BV; and NER at 1.0x P/BV.

Big caps OR, IVL, SCC, CPN are trading at enticing valuations

CPN still is traded at 2.2x P/BV on strong net profit growth and sustainability of portfolio of shopping malls, hotels, offices, and property. OR’s net profit is on brighter side, backed by growing café Amazon and benefits of asset restructuring. IVL is Thailand only global company with production presence globally that should allow IVL to grow net profits amid the higher import tariffs. SCC is the last man standing on its four-segment asset portfolio, potentially seeing earnings rebounds on chemical unit when the ethane feedstock is fed by 2027 while other segments of SCGP, SCGD, and SJWD, all likely to witness improving earnings outlook passing their worst bottoms.

SME caps PTG, SFLEX, PJW, and NER all seeing only uptrend growths

AT 1.3x P/BV, PTG sits on the point to see net profit growth from its lucrative non-oil café PunThai and LPG. SFLEX is a small-cap stock that is projected to see a series of record high quarterly net profits in 2025E on strong packaging portfolio. PJW’s net profit in 2025E is now poised to grow substantially on rising net profits from two new healthcare-related ventures of industrial laundry and medical disposable equipment. NER is a rubber stock that is trading below 5x P/E despite its strong net profit growth and visibility. NER’s major shifts in growth strategy to expand capacity by 60% and optimize hedging portion at 80% should propel its net profit growth.

SET to sideway in the range of 1,180-1,250 in March 2025

We think SET index will have limited upside at 1,300 in 2025E given the weak economic growth outlook, weak competitiveness of large-cap stocks, and most importantly, the ground-to-halt investors’ confidence in SET. Only bottom-up analysis is relevant to identify winning stocks based on limited downsides and visible upsides.

Analyst

Suwat Sinsadok
Suwat.s@globlex.co.th,
+662 687 7026

Analyst

Siriluck Pinthusoonthorn
Siriluck@globlex.co.th,
+662 672 5806

Assistant Analyst

Peerayu Sirivorawong

Exhibit 1: Prospective P/BV band - PTT



Sources: Bloomberg, Glolex Research

Exhibit 2: Prospective P/BV band - PTTEP




Sources: Bloomberg, Glolex Research

Exhibit 3: Prospective P/BV band - TOP




Sources: Bloomberg, Glolex Research

Exhibit 4: Prospective P/BV band - SPRC




Sources: Bloomberg, Glolex Research

Exhibit 5: Prospective P/BV band - BCP




Sources: Bloomberg, Glolex Research

Exhibit 6: Prospective P/BV band - BSRC



Sources: Bloomberg, Glolex Research

Exhibit 7: Prospective P/BV band - OR



Sources: Bloomberg, Glolex Research

Exhibit 8: Prospective P/BV band - PTG



Sources: Bloomberg, Glolex Research

Exhibit 9: Prospective P/BV band - SUSCO



Sources: Bloomberg, Glolex Research

Exhibit 10: Prospective P/BV band - TASCO




Sources: Bloomberg, Glolex Research

Exhibit 11: Prospective P/BV band - AAI



Sources: Bloomberg, Glolex Research

Exhibit 12: Prospective P/BV band - ITC



Sources: Bloomberg, Glolex Research

Exhibit 13: Prospective P/BV band - PTTGC



Sources: Bloomberg, Globlex Research

Exhibit 14: Prospective P/BV band - IRPC



Sources: Bloomberg, Globlex Research

Exhibit 15: Prospective P/BV band - IVL



Sources: Bloomberg, Globlex Research

Exhibit 16: Prospective P/BV band - SCC




Sources: Bloomberg, Globlex Research

Exhibit 17: Prospective P/BV band - EPG



Sources: Bloomberg, Globlex Research

Exhibit 18: Prospective P/BV band - BBGI




Sources: Bloomberg, Globlex Research

Exhibit 19: Prospective P/BV band - SFLEX



Sources: Bloomberg, Globlex Research

Exhibit 20: Prospective P/BV band - PJW



Sources: Bloomberg, Globlex Research

Exhibit 21: Prospective P/BV band - NER




Sources: Bloomberg, Globlex Research

Exhibit 22: Prospective P/BV band - STA




Sources: Bloomberg, Globlex Research

Exhibit 23: Prospective P/BV band - STGT




Sources: Bloomberg, Globlex Research

Exhibit 24: Prospective P/BV band - OKJ




Sources: Bloomberg, Globlex Research

Exhibit 25: Prospective P/BV band - CPALL




Sources: Bloomberg, Glolex Research

Exhibit 26: Prospective P/BV band - CPAXT




Sources: Bloomberg, Glolex Research

Exhibit 27: Prospective P/BV band - CPN




Sources: Bloomberg, Glolex Research

Exhibit 28: Prospective P/BV band - CRC




Sources: Bloomberg, Glolex Research

Exhibit 29: Prospective P/BV band - KAMART




Sources: Bloomberg, Glolex Research

Exhibit 30: Prospective P/BV band - MOSHI




Sources: Bloomberg, Glolex Research

Exhibit 31: Prospective P/BV band – COM7



Sources: Bloomberg, Glolex Research

Exhibit 32: Prospective P/BV band - SPA



Sources: Bloomberg, Glolex Research

GENERAL DISCLAIMER

Analyst Certification

Siriluck Pinthusoonthorn, Register No. 119539, Globlex Securities Public Company Limited

The opinions and information presented in this report are those of the Globlex Securities Co. Ltd. Research Department. No representation or warranty in any form regarding the accuracy, completeness, correctness or fairness of opinions and information of this report is offered by Globlex Securities Co. Ltd. Globlex Securities Co. Ltd. Accepts no liability whatsoever for any loss arising from the use of this report or its contents. This report (in whole or in part) may not be reproduced or published without the express permission of Globlex Securities Co. Ltd.

RECOMMENDATION STRUCTURE

Stock Recommendations

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

- BUY:** Expected return of 10% or more over the next 12 months.
HOLD: Expected return between -10% and 10% over the next 12 months.
REDUCE: Expected return of -10% or worse over the next 12 months.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Sector Recommendations

- Overweight:** The industry is expected to outperform the relevant primary market index over the next 12 months.
Neutral: The industry is expected to perform in line with the relevant primary market index over the next 12 months.
Underweight: The industry is expected to underperform the relevant primary market index over the next 12 months.

Country (Strategy) Recommendations

Overweight: Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral: Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight: Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.